Consensus Conference to Assess Adjuvant Therapy for Breast Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 3
Volume 9
Issue 3

BETHESDA, Md-The National Institutes of Health will convene a consensus development conference on adjuvant therapy for breast cancer on November 1–3, 2000.

BETHESDA, Md—The National Institutes of Health will convene a consensus development conference on adjuvant therapy for breast cancer on November 1–3, 2000.

The meeting will consider new information on chemotherapy, hormonal therapy, and other treatment aspects, including the clinical use of prognostic markers and quality-of-life issues. A panel of experts from outside NIH will make recommendations after hearing 2 days of presentations by leading researchers. The last breast cancer consensus conference on adjuvent therapy was in 1990.

Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.